Cost Savings Related to Qualifying Cell and Gene Therapy Facilities (On-Demand)

Curriculum

Course Description:

Viral vector and cell/gene therapy facilities can be less complicated and require fewer critical utilities when compared to pharmaceutical or biotech facilities. Such facilities frequently do not have specialized requirements such as low particulate levels or high-quality water systems as many processes are small-scale and enclosed. Viral vector facilities usually require multiple laboratories to perform assays and rooms to house controlled temperature units that require nothing more than adequate power and controlled classified environments. This webinar will discuss risk assessment and qualification that is phase-appropriate for your CGT operation.

From a regulatory perspective, there is ongoing reduction in prescriptive practices and while facility/utility qualification is rarely mentioned specifically, the implication is clear: it is not necessary to undertake the formulaic qualifications of years past. Instead, focused evaluation is limited to areas where assessments indicate higher risk and to those items most critical to intermediate and end-product quality (safety, purity, etc.).

- Be realistic about environmental and utility requirements for closed and enclosed processes

- Consider SaaS and similar to reduce upfront investment for implementation and qualification of computer-based functions.

- Determine the level of QMS and qualification that’s phase-appropriate for your operation

Who should participate:

Drug manufacturing, pharmaceutical manufacturing, biologics organizations, medical devices; Job function: quality assurance (QA), quality control (QC), operations managers, capital project managers, quality management, pharmaceutical quality directors.

The live version of this recording took place on May 24, 2023

Access Duration: Access to this course expires 60 days from the date of registration or until you mark the course ‘Complete’ – whichever occurs first.

Though this course is being made available on USP’s Education site, the course content was developed by Pharmatech Associates, a USP company.  USP has not independently reviewed or verified the accuracy of the course content.

Speaker:

 

Moria Feighery-Ross, CQA, CMQ/OE
Senior Consultant
Pharmatech Associates
B.Sc. biology, University of California, San Diego